Prostate MR AI (VA10A)

Siemens Healthcare GmbH's Prostate MR AI (VA10A) is a radiological CADe/CADx software that employs AI to automatically segment the prostate gland, detect suspicious regions for cancer, and provide a PI-RADS interpretation suggestion from non-contrast T2-weighted and diffusion-weighted MRI series. This software functions as a concurrent reading aid, demonstrating in clinical studies a significant improvement in radiologists' diagnostic performance and interreader agreement for prostate cancer detection.

Siemens Healthcare GmbH's Prostate MR AI (VA10A) is a Radiological Computer Assisted Detection and Diagnosis (CADe/CADx) software. It is designed as a concurrent reading aid to assist radiologists in interpreting prostate MRI examinations for adult men aged 40 and older who are suspected of having cancer in treatment-naïve prostate glands. The software analyzes non-contrast T2-weighted (T2W) and diffusion-weighted image (DWI) series to automatically segment the prostate gland, detect and segment regions suspicious for cancer, and provide a lesion score, including a PI-RADS interpretation suggestion. The output also includes a suspicion map, but patient management decisions should not be made solely based on the algorithm's analysis. This software has been reviewed and determined to be substantially equivalent to a legally marketed predicate device. This determination is based on the software performing the same fundamental function and role in medical practice as the predicate. Comprehensive non-clinical testing was conducted, including automated prostate segmentation, lesion detection, and classification performance tests. A multi-reader multi-case clinical study further demonstrated that radiologists' diagnostic performance and interreader agreement significantly improved when aided by the software. The product adheres to relevant international standards and general control provisions, ensuring its safety and effectiveness for its intended use.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What is the quantitative breakdown of sensitivity, specificity, and accuracy for the AI's lesion detection and classification capabilities?; How adaptable is the AI software to different MRI scanner manufacturers, field strengths, and specific pulse sequences beyond standard T2W and DWI?; Are there specific types of prostate cancer lesions (e.g., small, multifocal, or those in difficult anatomical locations) where the AI performance is particularly strong or weak?; What post-market surveillance or continuous learning mechanisms are in place to ensure the software maintains or improves its performance over time with new data?; Beyond PI-RADS suggestions, does the software provide any additional quantitative metrics (e.g., lesion volume, ADC values) that could enhance diagnostic confidence or guide biopsy?